Literature DB >> 26177827

Impact of EGFR and p53 expressions on survival and quality of life in locally advanced oral squamous cell carcinoma patients treated with chemoradiation.

Seema Gupta1, Huma Khan1, Vandana Singh Kushwaha1, Nuzhat Husain2, Mps Negi3, Ashim Ghatak3, Mlb Bhatt1.   

Abstract

EGFR and p53 are molecular markers which play important role in tumor progression and development. The objective of this study was to assess the association between EGFR and p53 expression and survival, and to determine whether EGFR and p53 expression levels were associated with differences quality of life in OSCC patients undergoing chemoradiation. A total of 120 OSCC patients aged 20-67 y and stage III/IV were recruited. Treatment response was assessed according to W.H.O. (1979). EGFR and p53 expression in tumor tissue was estimated by immunohistochemical (IHC) method and quantified as percentage positive nuclei. Molecular marker expressions of both EGFR and p53 were found significantly (P < 0.01 or P < 0.001) associated with overall response, survivals and quality of life. Neither EGFR nor p53 expression was associated with hematologic or non-hematologic toxicity. EGFR and p53 molecular marker expressions may have significant association with survival and QOL in OSCC patients undergoing chemoradiation.

Entities:  

Keywords:  chemoradition; immunohistochemistry; oral squamous cell carcinoma; quality of life; survival endpoints; toxicity

Mesh:

Substances:

Year:  2015        PMID: 26177827      PMCID: PMC4622606          DOI: 10.1080/15384047.2015.1070985

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  36 in total

1.  p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.

Authors:  S Temam; A Flahault; S Périé; G Monceaux; F Coulet; P Callard; J F Bernaudin; J L St Guily; P Fouret
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

2.  Late treatment effects: reframing the questions.

Authors:  Barbara A Murphy
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

Review 3.  Oral squamous cell carcinoma overview.

Authors:  Crispian Scully; Jose Bagan
Journal:  Oral Oncol       Date:  2009-02-26       Impact factor: 5.337

4.  Prognostic value of p53 genetic changes in colorectal cancer.

Authors:  U Kressner; M Inganäs; S Byding; I Blikstad; L Påhlman; B Glimelius; G Lindmark
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

5.  p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.

Authors:  S Tortola; E Marcuello; I González; G Reyes; R Arribas; G Aiza; F J Sancho; M A Peinado; G Capella
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

Review 6.  The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

Authors:  C L Arteaga
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

7.  Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study.

Authors:  H Raybaud-Diogène; A Fortin; R Morency; J Roy; R A Monteil; B Têtu
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

8.  The incidence of p53 mutations increases with progression of head and neck cancer.

Authors:  J O Boyle; J Hakim; W Koch; P van der Riet; R H Hruban; R A Roa; R Correo; Y J Eby; J M Ruppert; D Sidransky
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

9.  Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: does it make a difference?

Authors:  V M Patil; V Noronha; Amit Joshi; V K Muddu; S Gulia; B Bhosale; S Arya; S Juvekar; P Chatturvedi; D A Chaukar; P Pai; A D'cruz; K Prabhash
Journal:  Indian J Cancer       Date:  2013 Jan-Mar       Impact factor: 1.224

10.  The Role of p53 and MDM2 in Head and Neck Cancer.

Authors:  N Denaro; C Lo Nigro; G Natoli; E G Russi; V Adamo; M C Merlano
Journal:  ISRN Otolaryngol       Date:  2011-12-07
View more
  3 in total

1.  Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation.

Authors:  Seema Gupta; Vandana Singh Kushwaha; Sandeep Verma; Huma Khan; M L B Bhatt; Nuzhat Husain; Mahendra Pal Singh Negi; Vivek Vidyadhar Bhosale; Ashim Ghatak
Journal:  Heliyon       Date:  2016-12-05

2.  EGFR and Cortactin: Markers for potential double target therapy in oral squamous cell carcinoma.

Authors:  Oliver Bissinger; Andreas Kolk; Enken Drecoll; Melanie Straub; Christina Lutz; Klaus-Dietrich Wolff; Carolin Götz
Journal:  Exp Ther Med       Date:  2017-09-18       Impact factor: 2.447

3.  The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.

Authors:  Pina Ziranu; Eleonora Lai; Marta Schirripa; Marco Puzzoni; Mara Persano; Andrea Pretta; Giada Munari; Nicole Liscia; Valeria Pusceddu; Fotios Loupakis; Laura Demurtas; Michela Libertini; Stefano Mariani; Marco Migliari; Marco Dubois; Riccardo Giampieri; Giovanni Sotgiu; Angelo Paolo Dei Tos; Sara Lonardi; Alberto Zaniboni; Matteo Fassan; Mario Scartozzi
Journal:  Target Oncol       Date:  2021-05-10       Impact factor: 4.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.